You just read:

PharmaMar Initiates a Pivotal Phase III ATLANTIS Study with PM1183 in Combination with Doxorubicin in Patients with Small Cell Lung Cancer

News provided by

PharmaMar

02 Aug, 2016, 09:00 BST